On July 21, Sunshine Medical Procurement All-in-one issued the Notice on Collecting Basic Information Related to Certain Drugs, which points out that the basic information acquisition of certain drugs would be carried out, in order support the centralized drug procurement work and optimize the work process. The information acquisition involves 86 drugs.

Screenshot from Sunshine Medical Procurement All-in-one 

The Notice indicates that the information acquisition has put forward clear requirements for drug requirements, enterprises, acquisition content, etc. The information acquisition is only used for investigation and research of related work, but not as the basis for the application of centralized drug procurement enterprises. The qualifications for specific enterprise applicants and applied products should be in accordance with the procurement documents. 

Requirements for drugs 

The drugs should be the marketed ones within the scope of information acquisition, which have been provided with valid domestic registration approval documents and meet one of the following requirements: 

♦ The brand-name drugs and the reference listed drugs, which have been certified for the quality and efficacy consistency of generic drugs by the National Medical Products Administration.

♦ Generic drugs, which have been certified for the quality and efficacy consistency of generic drugs by the National Medical Products Administration. 

♦ Generic drugs approved under the new registration classification of chemical drugs according to the Announcement of the State Food and Drug Administration on Issuing the Work Plan for Reform of Chemical Drug Registration Classification [2016 No. 51]. 

♦ Drugs included in the Catalogue of China's Marketed Drugs.

Enterprises 

Relevant companies that fall within the scope of this information acquisition and meet drug requirements, including: domestic drug manufacturers offering drugs and accompanying services, holders of drug marketing licenses, and representative offices or corporations established or designated by overseas production enterprises in Chinese Mainland and capable of assuming corresponding legal responsibilities. 

Contents of acquisition

♦ Manufacturers, holders of drug marketing licenses, and representative offices or corporations established or designated by overseas production enterprises in Chinese Mainland and capable of assuming corresponding legal responsibilities (including company name, unified social credit code, contact person, and authorization letter).

♦ Evidences of compliance with drug requirements (including approval documents for drug registration and supplementary registration, and instructions). 

♦ Production capacity and API self-production instructions, etc. 

Attachment: Information Acquisition Scope Table 

Figure from Medical Cloud Studio 

Source: Menet